☆ 4.6 Letter

Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Get Full Text
Add to Collection

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 188, Issue 3, Pages E24-E27

Publisher

WILEY
DOI: 10.1111/bjh.16282

Keywords

AL-Amyloidosis; daratumumab; frailty

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.